Biolux Research, developer of OrthoPulse®, is pleased to announce the renewal of its partnership with the Schulman Study Group in an agreement to promote and provide innovative photobiomodulation products to Schulman orthodontic practices and patients.
The Schulman Study Group is a nationally-recognized association of prominent orthodontic practices. Membership is extended exclusively by invitation to sustain the same high standard of practice performance and to provide access to new technology and opportunities for innovation and insight that orthodontists would not otherwise find. The Schulman Study Group members share a commitment to exceptional patient care, quality of orthodontic experience, and continuing education. www.schulmanstudygroup.com.
Previously, members of the Schulman Study Group participated in a beta evaluation of OrthoPulse®, Biolux’s flagship product for accelerating orthodontic treatment, in the United States and Canada. The initial evaluation program allowed for early, preapproval, experience by Schulman member doctors to evaluate the commercial viability of OrthoPulse® in clinical practice.
OrthoPulse® is a clinically-proven medical device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement, thus reducing treatment time. OrthoPulse® received FDA clearance in July of 2015 and is cleared by the FDA for use with both braces and clear aligners. The device is designed to be used by patients on a daily basis for a total of 10 minutes, either at home or while traveling. The clinical evidence acquired to date shows a significant reduction of treatment time for patients undergoing orthodontic treatment, and feedback from patients and doctors indicates that photobiomodulation helps to reduce discomfort typically experienced by orthodontic patients.
“In the world of accelerated orthodontics, it’s comforting to find a company that under-promises and over-delivers. OrthoPulse® speeds up orthodontic treatment, reduces the discomfort associated with tooth movement and accelerates bone remodelling during the retention period. I love OrthoPulse® and my patients do too,” states Ron Redmond DDS, MS, CEO of the Schulman Study Group,
“We look forward to continuing our close relationship with Dr. Redmond and the Schulman Group,” echoes Kevin Strange, President and CEO of Biolux. “We feel that, by working together with these prominent orthodontists and their focus on innovation and exceptional patient care, we can significantly expand awareness of and interest in OrthoPulse® for the benefit of patients and doctors. We expect Light Accelerated Orthodontics™ to be a game-changer for patients.”
About Biolux Research
Biolux Research is a world leader in the development of innovative Light Accelerated Orthodontics™ technology and products for use in orthodontics, implantology, and other dentistry markets. Biolux Research focuses on product development and clinical research, and its proprietary, patented technologies have been developed to enhance clinical outcomes and dramatically reduce treatment timelines in orthodontics and dentistry in a safe, effective and non-invasive approach. www.orthopulse.com www.bioluxresearch.com
